These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19243020)

  • 1. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
    Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
    Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
    Adulnirath A; Chung SW; Park J; Hwang SR; Kim JY; Yang VC; Kim SY; Moon HT; Byun Y
    J Control Release; 2012 Nov; 164(1):8-16. PubMed ID: 23063549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
    Bae SM; Kim JH; Chung SW; Byun Y; Kim SY; Lee BH; Kim IS; Park RW
    Biomaterials; 2013 Mar; 34(8):2077-86. PubMed ID: 23245333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
    Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
    J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
    J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.
    Kim JY; Chung SW; Kim SY; Byun Y
    Pharm Res; 2015 Jul; 32(7):2318-27. PubMed ID: 25585956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
    Chung SW; Lee M; Bae SM; Park J; Jeon OC; Lee HS; Choe H; Kim HS; Lee BS; Park RW; Kim SY; Byun Y
    Biomaterials; 2012 Dec; 33(35):9070-9. PubMed ID: 23010574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
    Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
    Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.
    Alam F; Chung SW; Hwang SR; Kim JY; Park J; Moon HT; Byun Y
    J Appl Toxicol; 2015 Jan; 35(1):104-15. PubMed ID: 24532548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention.
    Kim JY; Al-Hilal TA; Chung SW; Kim SY; Ryu GH; Son WC; Byun Y
    J Control Release; 2015 Feb; 199():122-31. PubMed ID: 25523032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
    Kim JY; Shim G; Choi HW; Park J; Chung SW; Kim S; Kim K; Kwon IC; Kim CW; Kim SY; Yang VC; Oh YK; Byun Y
    Biomaterials; 2012 Jun; 33(17):4424-30. PubMed ID: 22425551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models.
    Alam F; Hwang SR; Al-Hilal TA; Chung SW; Kim HS; Kang BH; Zhang HS; Shin SH; Lee JY; Kang MS; Kwon GH; Jeon OC; Kim SY; Byun Y
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1247-57. PubMed ID: 26612099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin.
    Cheng W; Dahmani FZ; Zhang J; Xiong H; Wu Y; Yin L; Zhou J; Yao J
    Nanotechnology; 2017 Feb; 28(7):075102. PubMed ID: 28091396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.